A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

Part of paid clinical trials in Decatur, Alabama.

Sponsor
Maze Therapeutics
Study ID
NCT06830629
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Proteinuric Kidney Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 68 Years
Healthy Volunteers
Not accepted

Interventions

  • MZE829 — DRUG
    Capsules for oral administration

Study Details

The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.

Key Dates

First listed
Feb 17, 2025
Start date
Feb 5, 2025
Status verified
Jul 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
74 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: MZE829
    Cohort 1: Chronic kidney disease with concurrent diabetes Cohort 2: Chronic kidney disease without concurrent diabetes

Primary Outcome Measure

Safety and tolerability as assessed by incidence of adverse events (AEs) [ Time Frame: Baseline to Week 12 ]

Central Contacts

Locations (68)

FacilityCityStateZIPSite coordinators
Research SiteDecaturAlabama35601-
Research SiteHuntsvilleAlabama35805-
Research SiteMontgomeryAlabama36106-
Research SiteMontgomeryAlabama36117-
Research SiteBloomfieldConnecticut06112-
Research SiteWashington D.C.District of Columbia20060-
Research SiteAtlantisFlorida33462-
Research SiteBrandonFlorida33511-
Research SiteHollywoodFlorida33024-
Research SiteMelbourneFlorida32901-
Research SiteOrlandoFlorida32822-
Research SiteAtlantaGeorgia30309-
Research SiteCollege ParkGeorgia30349-
Research SiteCordeleGeorgia31015-
Research SiteMaconGeorgia31210-
Research SiteRiverdaleGeorgia30274-
Research SiteRiverdaleGeorgia30296-
Research SiteSavannahGeorgia31406-
Research SiteSnellvilleGeorgia30078-
Research SiteChicagoIllinois60616-
Research SiteChicagoIllinois60643-
Research SiteEvanstonIllinois60201-
Research SiteKansas CityKansas66112-
Research SiteBowling GreenKentucky42101-
Research SiteLouisvilleKentucky40205-
Research SiteArnoldMaryland21012-
Research SiteLuthervilleMaryland21093-
Research SiteOxon HillMaryland20745-
Research SiteDearbornMichigan48126-
Research SiteFlintMichigan48503-
Research SitePontiacMichigan48341-
Research SiteSaint JosephMichigan49085-
Research SiteMinneapolisMinnesota55404-
Research SiteTupeloMississippi38801-
Research SiteCity of Saint PetersMissouri63376-
Research SiteSt LouisMissouri63103-
Research SiteLas VegasNevada89107-
Research SiteJersey CityNew Jersey07305-
Research SiteBuffaloNew York14203-
Research SiteLaureltonNew York11413-
Research SiteMaspethNew York11378-
Research SiteNewburghNew York12550-
Research SiteDurhamNorth Carolina27708-
Research SiteFayettevilleNorth Carolina28304-
Research SiteGreensboroNorth Carolina27405-
Research SiteShelbyNorth Carolina28150-
Research SiteClevelandOhio44106-
Research SiteClevelandOhio44195-
Research SiteColumbusOhio43215-
Research SiteArdmoreOklahoma73401-
Research SitePhiladelphiaPennsylvania19104-
Research SitePhiladelphiaPennsylvania19107-
Research SiteUplandPennsylvania19013-
Research SiteColumbiaSouth Carolina29203-
Research SiteSpartanburgSouth Carolina29302-
Research SiteSpartanburgSouth Carolina29306-
Research SiteChattanoogaTennessee37404-
Research SiteDallasTexas75230-
Research SiteDallasTexas75246-
Research SiteGreenvilleTexas75402-
Research SiteHoustonTexas77030-
Research SiteHoustonTexas77054-
Research SiteHoustonTexas77099-
Research SiteMcKinneyTexas75069-
Research SiteSan AntonioTexas78251-
Research SiteShenandoahTexas77384-
Research SiteShermanTexas75092-
Research SiteNorfolkVirginia23504-

Related Studies